The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors

Figure 3. In the base case, the annual cost of ACE inhibitor therapy is $320 and the relative risk for progression to microalbuminuria is 0.32. QALY = quality-adjusted life-year.
Figure 3. In the base case, the annual cost of ACE inhibitor therapy is $320 and the relative risk for progression to microalbuminuria is 0.32. QALY = quality-adjusted life-year. Cost-effectiveness of the “treat all” strategy relative to the “screen for microalbuminuria” strategy as a function of cost of angiotensin-converting enzyme (ACE) inhibitors (top) or relative risk for progression to microalbuminuria (bottom) and age at diagnosis.

This Article

  1. Ann Intern Med November 2, 1999 vol. 131 no. 9 660-667
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues